Background {#Sec1}
==========

Breast cancer (BC) is a heterogeneous disease, which encompasses various entities showing significant differences in morphologic and prognostic features, as well as in therapeutic options \[[@CR1]\]. Recently, a marked molecular heterogeneity of breast cancer has also been demonstrated by gene expression profiling studies, which identified four major BC "*intrinsic*" subtypes, including luminal A, luminal B, HER2-enriched, and basal-like, showing variable biological, clinical behaviors and response to treatment \[[@CR2], [@CR3]\]. So far, invasive breast cancer has been classified according to histological features and immunohistochemical expression of estrogen receptors (ER), progesterone receptors (PR) and HER2 overexpression and/or *HER2* gene amplification \[[@CR4]\]. Interestingly, BC subtyping by immunohistochemistry (IHC) is concordant with gene expression profiles, therefore having significant clinical utility \[[@CR5], [@CR6]\].

Particularly, ER/PR/HER2 negative immunostain defines the Triple Negative subtype, which accounts for 10 -20% of all invasive breast cancer types. TNBC is most prevalent in young women, \< 50 years of age, showing aggressive clinical behavior, high histological grade and poor prognosis, and is responsible for about 25% of BC-related deaths. TNBC comprehends tumors with different clinico-pathological features and genetic-molecular alterations \[[@CR7]\], and it is prevalently histological categorized as IBC-NST. Other histologic "*special types*" (HST), such as metaplastic, apocrine, lobular and adenoid cystic carcinomas, are still included among TNBC. These special phenotypes substantially differ in terms of biological behavior and clinical course \[[@CR8]\]. Among TNBC histotypes, the historical morphological entity of medullary carcinoma previously considered as a specific BC special type in the category of "carcinoma with medullary features", is no longer identified as a special type variant and has been recently reconsidered as IBC-NST with medullary pattern, rather than a distinct morphological subtype; moreover, medullary-type pattern is often associated with variable immunohistochemical expression of basal markers \[[@CR9]\].

Recent studies evaluated the outcome of patients with TNBC special types showing that distinct prognostic implications derive from these morphologic features, highlighting that the identification of the special types has a significant clinical utility, and should be considered in therapeutic algorithms \[[@CR10]--[@CR14]\].

The aim of this study was to analyze a uniquely large cohort of TNBC patients enrolled in Sardinia, Italy, in order to evaluate the clinico-pathological heterogeneity, taking into account several parameters known for their prognostic and predictive roles, as well as highlighting the correlation between tumor size and lymph nodes status according to TNBC histologic subtypes. The prognostic significance of histologic special types compared with IBC-NST triple negative variants was also investigated.

Methods {#Sec2}
=======

The study was conducted in accordance with the code of ethics of the World Medical Association (Declaration of Helsinki). The protocol was approved by the local research ethics committee of Sardinia Region (File number 224/CE/12); according to the Italian legislation on guidelines for the implementation of retrospective observational studies (G.U. n. 76, 31/03/2008) it renounced the written informed consent from patients. To protect patient confidentiality, only coded data without direct patient identifiers were collected. Information was obtained from retrospectively collected *TNBC Database* on all consecutive patients with Triple Negative breast cancer diagnosis surgically treated in the four most important Oncology Units located in different hospitals in Sardinia, from 1994 to 2015, as previously published \[[@CR15]\]. Specifically, in the present study, a total of 1009 primary TNBC patients were recruited based on further revision and integrations of TNBC patients in our dynamic *TNBC Database*. Three experienced pathologists reviewed all tumors cases independently, and histologic subtyping has achieved according to current WHO classification \[[@CR16]\].

Immunohistochemical analysis {#Sec3}
----------------------------

ER, PR, and HER2 immunohistochemical expression and/or *HER2* gene amplification, as defined by silver-enhanced "in situ" hybridization (SISH), established TNBC status. The IHC analysis was performed using specific antibodies against monoclonal rabbit ER antibody, Clone SP1 (Neomarker, Fremont, CA USA), monoclonal mouse PR antibody, Clone PgR 636 (DakoCytomation, Glostrup, Denmark). Moreover, Ki-67 and androgen receptors (AR), were also evaluated with monoclonal mouse Ki-67, clone MM1 (Leica Biosystems, Wetzlar, Germania) and mouse monoclonal AR, clone 2F12, (Novocastra, Dublin, OH, USA), respectively.

ER, and PR expression were positive if at least 1% immunostained tumor nuclei were detected in the sample, according to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) recommendations for immunohistochemical testing of hormone receptors in BC \[[@CR17]\], whose criteria have recently been adopted by WHO classification \[[@CR16]\].

AR expression was considered positive if at least 1% immunostained tumor nuclei were detected in the sample and categorized using semi-quantitative expression \[[@CR18]\]. The Ki67 cut-off \< 14, 15--30% and \> 30% were based on results obtained in our previous study by Urru et al. 2018 \[[@CR15]\]. HER2 protein expression was determined using FDA approved HercepTest™ K5206 (DakoCytomation) and evaluated according to the manufacturer's instructions. *HER2* gene amplification was ascertained by ultra-View SISH Detection Kit (Ventana Medical Systems, Tucson, USA).

Given that the study included patients diagnosed over almost 20 years in different hospital centers, all surgical specimens of TNBC patients were reviewed independently by three experienced pathologists to achieve a consensus on morphologic criteria and to standardize the results according to the current guidelines recommendations for ER, PgR and HER2 immunohistochemistry \[[@CR17]\]. Older cases, mainly from 1994 to 2005, and selected cases with not concordant morphology were immunostained again according to the protocol mentioned above.

Patient information {#Sec4}
-------------------

*TNBC Database* includes personal and medical data collected from medical records of each TNBC patient. Specifically, it includes patients' information on socio-demographic factors, anthropometric characteristics, obstetric and gynecologic features, lifestyle habits, family history of breast and other cancers, and various comorbidities. Moreover, pathologic assessments included information on tumor site and size, histologic type and grade, necrosis, lymphovascular invasion (LVI), AR and Ki67 expression, lymph node status, tumor grade, and pathologic TNM staging. Finally, tumor-infiltrating lymphocytes (TILs) were analyzed according to Denkert et al. criteria \[[@CR19]\] and scored semi-quantitatively in two categories, low TILs (\< 50.0%) and high TILs (\> 50.0%), according to previous experiences \[[@CR20]\]. Lymph node ratio was obtained from the number of metastatic lymph node divided by the number of lymph node evaluated by pathologist, and was categorized according to validated cut-off points, i.e. ≤ 0.2, 0.21--0.65, and ≥ 0.65 \[[@CR21]\]. Finally, all clinical data of TNBC patients, including cancer treatments (surgery, radiotherapy and/or chemotherapy), TNBC recurrence, occurrence of other neoplasm(s), metastasis or death, were recorded. The baseline and follow-up data were defined as previously reported \[[@CR15]\].

Statistical analysis {#Sec5}
--------------------

Overall survival and disease-free survival were the main endpoints of this study. OS is defined as the time between the date at diagnosis and the date of death, and the DFS as the time from the date at diagnosis to the date of TNBC local recurrence, clinical metastatic diseases, occurrence of other primary cancers, death, or last follow-up visit, whichever occurred first.

Descriptive overall and subgroup analysis were carried out and differences in the basic characteristics and clinical parameters were analyzed using the Student t-test for normal distributed variables; Chi-Square test or Fisher's exact test were used to test differences in frequencies, when appropriated, respectively. A violin plot analysis showed the distribution of tumor size according to histologic type. Mann-Whitney U test assessed the differences between histologic types. To study the relationship between tumor size (mm) and number of positive lymph nodes in different TNBC histological types, Spearman correlation and linear regression was used. In the linear regression model, the slope of the regression line indicates the mean increase in the number of positive nodes per millimeter of increase in tumor size. A *p* value for interaction was calculated to determine whether such effect varied significantly according to the histologic type. This analysis was limited to patients with at least five lymph nodes examined. All tests were two-sided, and a threshold of *p* \< 0.05 was considered to identify statistically significant results. No statistical adjustment was made for multiple comparisons.

Multivariate hazard ratios (HRs) for recurrence and mortality, after 10 years of follow-up, according to TNBC histologic types and the corresponding 95% confidence intervals (CIs), were calculated by Cox proportional hazards model, corrected for age, tumor size and number of positive lymph node. Kaplan-Meier method and Log-Rank test were utilized to describe DFS and OS according to TNBC histologic types. Statistical analysis was performed in R packages \"survminer\" and \"survival. The statistical significance was set-up at \< 0.05.

Results {#Sec6}
=======

Clinico-pathologic features of TNBC histologic types {#Sec7}
----------------------------------------------------

One thousand and nine TNBC patients were initially included in the study. Table [1](#Tab1){ref-type="table"} shows the pathological assessments including the overall distribution of TNBC according to histologic type. Tumors from 745 patients (78.1%) were classified as IBC-NST, 62 (6.5%) as lobular, 43 (4.5%) as apocrine, 42 (4.4%) as metaplastic, 39 (4.1%) as medullary; less common were other histologic types such as mixed IBC-NST and invasive lobular carcinoma (0.7%), papillary (0.7%), adenoid cystic (0.6%), mucinous (0.2%) and micropapillary (0.2%) carcinomas. Table 1Clinico-pathological features of "*Triple Negative*" breast cancerVariablesTNBC n (%)\
(*n* = 1009)\
n (%)**Age**  \< 3547 (4.7) 35--49263 (26.1) 50--69503 (49.9) 70+195 (19.3) Missing1**Site** Right429 (48.6) Left447 (50.7) Bilateral6 (0.7) Missing127**Histologic type** IBC-NST745 (78.1) Lobular62 (6.5) Mucinous2 (0.2) Medullary39 (4.1) Mixed IBC-NST and invasive lobular7 (0.7) Apocrine43 (4.5) Papillary7 (0.7) Adenoid cystic6 (0.6) Metaplastic42 (4.4) Micropapillary2 (0.2) Missing54**Histologic grade** G111 (1.1) G2204 (21.3) G3744 (77.6) Missing50**Tumor size** pT01 (0.1) pT1379 (40.6) pT2441 (47.3) pT359 (6.3) pT453 (5.7) Missing76**Lymph node status** pN0533 (59.4) pN1214 (23.9) pN290 (10.0) pN360 (6.7) Missing112**Metastasis** M0812 (95.8)) M136 (4.2 Missing161**TNM stage** I258 (29.1) II413 (46.5) III182 (20.5) IV35 (3.9) Missing121**Lymph node ratio**  \< 0,2717 (81.4) 0,21-0,65103 (11.7)  \> 0,6561 (6.9) Missing128**Lymphovascular invasion** yes349 (45.0) no427 (55.0) Missing233**Necrosis** Present491 (61.0) Absent314 (39.0) Missing184**Lymphocytic infiltrate** yes504 (64.5) no278 (35.5) Missing227**Proliferation index (Ki-67)**  \< 14%94 (9.9) 15--30%155 (16.4)  ≥ 30%698 (73.7) Missing62**Androgen Receptor** Positive125 (24.3) Negative389 (75.7) Missing495**Type of surgery** Mastectomy341 (42.2) Quadrantectomy451 (55.5) Lumpectomy17 (2.0) Missing200**Adjuvant chemotherapy** yes580 (57.5) no429 (42.5)**Adjuvant radiotherapy** yes364 (36.1) no645 (63.9)**Recurrence** yes67 (6.6) no942 (93.4)**Contralateral breast cancer** yes69 (6.8) no940 (93.2)*n* = number

Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"} outline the anamnestic data of TNBC patients and tumors characteristics according to histologic type. Patients affected by adenoid cystic (16.7%) or medullary (15.4%) carcinomas were frequently younger in age (\< 35 years), whereas apocrine carcinoma (41.9%) was more frequent at \> 70 years. The adenoid cystic tumors showed lower grade (G1) and low proliferation index (Ki67 \< 14.0%), accounting for 33.3 and 33.3% of samples, respectively. Metaplastic and medullary types showed higher grades (G3), namely 91.1 and 89.2%, respectively, as well as higher proliferation index (Ki67: \> 30.0%), with 84.4 and 89.5%, respectively. Lymph node ratio \< 0.2 was reported in adenoid cystic (100.0%), metaplastic (86.4%) and medullary (91.4%) types; the lobular type showed the higher lymph node ratio (\> 0.65), accounting for 20.4%. LVI was more frequent in lobular (51.6%) and apocrine carcinomas (50.0%); LVI was also detected in 33.3% of adenoid cystic and only in 7.4% of medullary carcinomas. No necrosis, TILs and AR expression were found in adenoid cystic carcinomas; the higher percentage of necrosis was identified in metaplastic carcinoma (83.7%), whereas the highest proportion of TILs was seen in medullary tumors (92.3%). As expected, lobular and apocrine types showed higher expression of AR than other histologic types. Table 2Anamnestic data of 1009 patients with "*Triple Negative"* breast cancer based on histologic subtypes. Sardinia, Italy 1994--2015IBC-NST\
(*n* = 744)\
n (%)Lobular\
(*n* = 62)\
n (%)Apocrine\
(*n* = 43)\
n (%)Adenoid cystic\
(*n* = 6)\
n (%)Metaplastic\
(*n* = 46)\
n (%)Medullary\
(*n* = 39)\
n (%)Other\
(*n* = 27)\
n (%)*p* value\***Age**  \< 3534 (4.6)0 (0.0)2 (4.7)1 (16.7)3 (6.5)6 (15.4)1 (3.7)**\< 0.001** 35--49214 (28.8)10 (16.1)1 (2.3)1 (16.7)8 (17.4)12 (30.8)8 (29.6) 50--69354 (47.6)36 (58.1)22 (51.2)3 (50.0)26 (56.5)18 (46.2)16 (59.3) 70+141 (19.0)16 (25.8)18 (41.9)1 (16.7)9 (19.6)3 (7.7)2 (7.4) Missing1**Age at menarche**  \< 13208 (45.9)10 (31.3)11 (37.9)0 (0.0)9 (27.3)7 (43.8)4 (19.0)**0.036**  ≥ 13245 (54.1)22 (68.8)18 (62.1)2 (100.0)24 (72.7)9 (56.3)17 (81.0) Missing29130144**Age at menopause**  \< 4534 (11.8)3 (12.0)2 (7.7)1 (50.0)1 (4.3)2 (18.2)1 (7.7)0.519  ≥ 45253 (88.2)22 (88.0)24 (92.3)1 (50.0)22 (95.7)9 (81.8)12 (92.3) Missing45737173232714**Menopausal status** yes210 (47.6)18 (66.7)17 (63.0)1 (33.3)20 (60.6)10 (52.6)12 (54.5)0.124 post surgical39 (8.8)3 (11.1)4 (14.8)1 (33.3)2 (6.1)2 (10.5)1 (4.5) post treatment2 (0.5)0 (0.0)1 (3.7)0 (0.0)0 (0.0)1 (5.3)0 (0.0) no190 (43.1)6 (22.2)5 (18.5)1 (33.3)11 (33.3)6 (31.6)9 (40.9) Missing3033516313205**Nulliparity** yes80 (16.4)1 (3.1)7 (25.0)0 (0.0)7 (19.4)4 (25.0)4 (20.0)0.280 no409 (83.6)31 (96.9)21 (75.0)3 (100.0)29 (80.6)12 (75.0)16 (80.0) Missing2553015310227**Family history of breast cancer** yes166 (33.8)9 (23.7)11 (36.7)3 (100.0)13 (37.1)9 (45.0)5 (21.7)0.104 no325 (66.2)29 (76.3)19 (63.3)0 (0.0)22 (62.9)11 (55.0)18 (78.3) Missing2532413311194**Family history of other than breast cancer** yes137 (29.1)14 (38.9)6 (20.7)0 (0.0)8 (25.0)6 (35.3)10 (45.5)0.309 no333 (70.9)22 (61.1)23 (79.3)3 (100.0)24 (75.0)11 (64.7)12 (54.5) Missing2742614314205**Other concomitant primary cancer** yes11 (4.5)1 (5.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0.870 no231 (95.5)19 (95.0)12 (100.0)2 (100.0)19 (100.0)8 (100.0)11 (100.0) Missing50242314273116**Other previous primary cancer** yes19 (7.3)1 (5.0)3 (20.0)0 (0.0)0 (0.0)1 (11.1)0 (0.0)0.361 no242 (92.7)19 (95.0)12 (80.0)2 (100.0)19 (100.0)8 (88.9)11 (100.0) Missing48342284273016**BMI**  \< 18 underweight14 (3.0)0 (0.0)0 (0.0)1 (33.3)0 (0.0)0 (0.0)2 (10.0)0.183 18--24.9 normal range235 (50.8)15 (46.9)11 (42.3)1 (33.3)18 (54.5)8 (47.1)8 (40.0) 25--30 overweight135 (29.2)11 (34.4)7 (26.9)1 (33.3)11 (33.3)7 (41.2)7 (35.0)  \> 30 0bese79 (17.1)6 (18.8)8 (30.8)0 (0.0)4 (12.1)2 (11.8)3 (15.0) Missing2813017313227**Drinking** yes21 (4.9)1 (3.1)0 (0.0)1 (33.3)0 (0.0)3 (21.4)1 (4.8)**0.015** no407 (95.1)31 (96.9)22 (100.0)2 (66.7)32 (100.0)11 (78.6)20 (95.2) Missing3163021314246**Smoking** yes92 (20.2)5 (14.7)4 (16.0)1 (3.3)7 (21.2)3 (18.8)3 (13.6)0.942 no364 (79.8)29 (85.3)21 (84.0)2 (66.7)26 (78.8)13 (81.3)19 (86.4) Missing2882818313225\*The *p*-value are bold where they are less than or equal to the significance level of 0.05Table 3Clinico-pathological data of 1009 patients with "*Triple Negative"* breast cancer based on histologic subtypes. Sardinia, Italy 1994--2015IBC-NST\
(*n* = 744)\
n (%)Lobular\
(*n* = 62)\
n (%)Apocrine\
(*n* = 43)\
n (%)Adenoid cystic\
(*n* = 6)\
n (%)Metaplastic\
(*n* = 46)\
(%)Medullary\
(*n* = 39)\
n (%)Other\
(*n* = 27)\
n (%)*p* value\***Site** Right328 (49.1)23 (52.2)15 (44.1)3 (50.0)16 (38.1)17 (48.6)12 (50.0)0.977 Left334 (50.0)21 (47.7)19 (55.9)3 (50.0)26 (61.9)18 (51.4)12 (50.0) Bilateral6 (0.9)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0) Missing76189443**Histologic grade** G15 (0.7)1 (2.0)2 (4.7)2 (33.3)0 (0.0)1 (2.7)1 (4.0)**\< 0.001** G2128 (17.8)25 (50.0)18 (41.9)3 (50.0)4 (8.9)3 (8.1)8 (32.0) G3588 (81.6)24 (48.0)23 (53.5)1 (16.7)41 (91.1)33 (89.2)16 (64.0) Missing2312122**Tumor size** pT01 (0.1)0 (0.0)0 (0.0)0 (0.0)0 (0.0.)0 (0.0)0 (0.0)0.110 pT1285 (39.7)14 (24.6)22 (51.2)5 (83.3)13 (28.3)17 (44.7)8 (32.0) pT2337 (47.0)32 (56.1)17 (39.5)1 (16.7)22 (47.8)17 (44.7)9 (36.0) pT332 (4.5)7 (12.3)3 (7.0)0 (0.0)9 (19.6)3 (7.9)4 (16.0) pT443 (6.0)2 (3.5)1 (2.3)0 (0.0)2 (4.3)1 (2.6)3 (12.0) pTx18 (2.5)2 (3.5)0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (4.0) Tis1 (0.1)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0) Missing27512**Lymph node status** pN0395 (56.3)22 (38.6)28 (65.1)3 (60.0)30 (65.2)24 (63.2)10 (40.0)0.190 pN1155 (22.1)15 (26.3)7 (16.3)2 (40.0)11 (23.9)11 (28.9)11 (44.0) pN268 (9.7)9 (15.8)5 (11.6)0 (0.0)4 (8.7)1 (2.6)2 (8.0) pN347 (6.7)7 (12.3)3 (7.0)0 (0.0)0 (0.0)1 (2.6)1 (4.0) pNx36 (5.1)4 (7.0)0 (0.0)0 (0.0)1 (2.2)1 (2.6)1 (4.0) Missing435112**Metastasis** M0649 (87.2)55 (88.7)41 (95.3)5 (83.3)41 (89.1)38 (97.4)21 (77.8)0.190 M195 (12.8)7 (11.3)2 (4.7)1 (16.7)5 (10.9)1 (2.6)6 (22.2)**TNM stage** I188 (28.5)8 (15.1)19 (44.2)3 (50.0)10 (22.2)11 (29.7)5 (21.7)0.210 II306 (46.4)27 (50.9)15 (34.9)2 (33.3)24 (53.3)23 (62.2)10 (43.5) III137 (20.8)15 (28.3)9 (20.9)1 (16.7)9 (20.0)2 (5.4)7 (30.4) IV28 (4.2)3 (5.7)0 (0.0)0 (0.0)2 (4.4)1 (2.7)1 (4.3) Missing859124**Lympho node ratio**  \< 0.2520 (81.0)35 (64.8)36 (85.7)5 (100.0)38 (86.4)32 (91.4)19 (82.6)**0.019** 0.21--0.6575 (11.7)8 (14.8)4 (9.5)0 (0.0)5 (11.4)3 (8.6)4 (17.4)  \> 0.6547 (7.3)11 (20.4)2 (4.8)0 (0.0)1 (2.3)0 (0.0)0 (0.0) Missing102811244**Proliferation index (Ki-67)**  \< 14%54 (7.6)20 (37.0)7 (16.3)2 (33.3)2 (4.4)2 (5.3)3 (11.1)**\< 0.001** 15--30%110 (15.6)11 (20.4)13 (30.2)1 (16.7)5 (11.1)2 (5.3)8 (29.6)  ≥ 30%542 (76.8)23 (42.6)23 (53.5)3 (50.0)38 (84.4)34 (89.5)16 (59.3) Missing38811**In situ component** Present112 (15.1)2 (3.2)8 (18.6)0 (0.0)3 (6.5)2 (5.1)4 (14.8)**0.038** Absent632 (84.9)60 (96.8)35 (81.4)6 (100.0)43 (93.5)37 (94.9)23 (85.2)**Lymphovascular invasion** yes276 (46.0)16 (51.6)18 (50.0)2 (33.3)18 (42.9)2 (7.4)12 (60.0)**0.004** no324 (54.0)15 (48.4)18 (50.0)4 (66.7)24 (57.1)25 (92.6)8 (40.0) Missing1443174127**Necrosis** Present388 (62.7)13 (37.1)15 (39.5)0 (0.0)36 (83.7)13 (50.0)12 (60.0)**\< 0.001** Absent231 (37.3)22 (62.9)23 (60.5)6 (100.0)7 (16.3)13 (50.0)8 (40.0) Missing1252753137**Lymphocytic infiltrate** yes397 (65.2)11 (36.7)27 (75.0)0 (0.0)24 (60.0)24 (92.3)13 (65.0)**\< 0.001** no212 (34.8)19 (63.3)9 (25.0)6 (100.0)16 (40.0)2 (7.7)7 (35.0) Missing1353276137**Androgen receptor** Positive79 (19.6)10 (76.9)24 (88.9)0 (0.0)3 (9.7)1 (6.3)4 (33.3)**\< 0.001** Negative324 (80.4)3 (23.1)3 (11.1)4 (100.0)28 (90.3)15 (93.8)8 (66.7) Missing34149162152315**Type of surgery** Mastectomy244 (40.7)23 (53.5)19 (51.4)0 (0.0)19 (59.4)12 (35.3)12 (50.0)0.369 Quadrantectomy342 (57.0)20 (46.5)18 (48.6)4 (100.0)21 (65.6)22 (64.7)11 (45.8) Lumpectomy14 (2.3)0 (0.0)0 (0.0)0 (0.0)2 (6.3)0 (0.0)1 (4.2) Missing1441962453**Adjuvant chemotherapy** yes436 (58.6)34 (54.8)25 (58.1)2 (33.3)29 (63.0)22 (56.4)19 (70.4)0.685 no308 (41.4)28 (45.2)18 (41.9)4 (66.7)17 (37.0)17 (43.6)8 (29.6)**Adjuvant radiotherapyyes**258 (34.7)17 (27.4)20 (46.5)1 (16.7)19 (41.3)14 (35.9)12 (44.4)**\< 0.001** no468 (65.3)45 (72.6)23 (53.5)5 (83.3)27 (58.7)25 (64.1)15 (55.6)\*The *p*-value are bold where they are less than or equal to the significance level of 0.05

Supplementary Figure 1 (see Additional file [1](#MOESM1){ref-type="media"}) shows the distribution of tumor size according to TNBC histologic type: using IBC-NST as a reference the adenoid cystic carcinoma displayed the smallest size (median size: 14.5 mm vs 21 mm for IBC-NST; *p* = 0.050), with the distributions of tumor size relatively concentrated \[Interquartile range (IQR): 13.2--18.7 mm\]. Although, apocrine, lobular and metaplastic carcinomas showed higher tumor size than IBC-NST, the *p* value did not achieve significance. A significant positive correlation between tumor size and number of metastatic lymph nodes was identified in apocrine and metaplastic carcinomas, with a Spearman correlation coefficient of 0.507, *p* = 0.031 and 0.384, *p* = 0.039, respectively (see Additional file [1](#MOESM1){ref-type="media"}: Supplementary Table 1). Linear regression model used to analyze the effect of tumor size on the number of metastatic lymph nodes, showing that the slope of the regression line for apocrine carcinoma (slope 0.171 vs 0.006; *p* = 0.040) was significantly higher than IBC-NST (see Additional file [1](#MOESM1){ref-type="media"}: Supplementary Figure 2).

Prognostic indicators according to TNBC histologic types {#Sec8}
--------------------------------------------------------

The Kaplan-Meier curves for DFS and OS according to TNBC histologic type did not show statistically significance with *p* = 0.110 and *p* = 0.340, respectively (Fig. [1](#Fig1){ref-type="fig"}). Although patients with adenoid cystic carcinoma had the best 1-year DFS (100.0%); conversely, patients with metaplastic carcinoma showed the worst DFS (89.1%). At five-years, DFS was similar for patients with lobular (87.0%), apocrine (86.0%), adenoid cystic (83.3%) and metaplastic (84.7%) carcinomas, while the patients affected by medullary carcinoma showed the best DFS (97.4%). At ten-years, patients with medullary carcinoma still showed the most favorable behavior (97.4% of cases), while patients with adenoid cystic carcinoma showed the highest rate of relapse (33.4%) among all types. Fig. 1Kaplan-Meier curves of disease free survival (**a**) and overall survival (**b**) of patients affected by "*Triple Negative*" breast cancer according to histologic types

Moreover, at 1-year follow-up OS was 100.0% for patients with adenoid cystic, apocrine and medullary carcinoma. At five-years, OS was 92.1, 100.0, and 94.5% for patients with apocrine, adenoid cystic and medullary carcinoma, respectively; conversely, patients affected by lobular and metaplastic carcinoma showed the worst OS, 79.7 and 84.3%, respectively. Finally, at ten-years, patients with adenoid cystic (100.0%) and medullary (94.5%) carcinoma had a more favorable prognosis, while patients with lobular carcinoma showed the worst prognosis (73.8%).

The multivariate analysis revealed that TNBC medullary type showed an independent prognostic factor for DFS compared to IBC-NST (HR, 0.12; 95% CI 0.01--0.87; *p* = 0.030). The same pattern was observed for OS, even though it was not statistically significant (Table [4](#Tab4){ref-type="table"}). Table 4Hazard ratios (HRs) of disease-free survival and mortality, and corresponding 95% of confidence intervals (CIs), according to histologic subtypes, among 1009 "*Triple Negative*" breast cancer. Sardinia, Italy 1994--2015Disease-free survivalOverall survivalUnivariate analysis\
HR (95% CI)Multivariate analysis^**a**^\
HR (95% CI)Univariate analysis\
HR (95% CI)Multivariate analysis^**a**^\
HR (95% CI)IBC-NST1.00^b^1.00^b^1.00^b^1.00^b^Lobular0.68 (0.33--1.39)0.57 (0.26--1.24)1.36 (0.79--2.33)1.06 (0.50--2.25)Apocrine1.40 (0.76--2.60)1.34 (0.71--2.49)0.77 (0.64--1.76)0.54 (0.17--1.73)Adenoid cystic1.85 (0.46--7.50)1.20 (0.16--8.69)----Metaplastic0.85 (0.40--1.83)0.75 (0.34--1.64)0.88 (0.39--2.01)0.60 (0.18--1.96)Medullary**0.13 (0.01--0.92)0.12 (0.01--0.87)**0.30 (0.07--1.21)0.42 (0.10--1.74)Other1.44 (0.67--3.09)1.33 (0.61--2.89)0.64 (0.20--2.04)0.17 (0.02--1.28)^a^Estimates from multivariate proportional hazard regression model adjusted for age, tumor size and number of positive nodes. Estimates in bold are those significant at the 0.05 level^b^Reference category

Discussion {#Sec9}
==========

The present study investigated the clinico-pathological features and prognosis of different TNBC histologic types. The incidence of TNBC histologic variants analyzed was concordant with other studies \[[@CR11], [@CR14], [@CR22]\].

Taking IBC-NST as a reference, our data showed that patients with lobular and metaplastic carcinoma had poor survival outcomes at 5- and 10-years follow-up; patients with adenoid cystic and medullary carcinoma had excellent prognosis at 5- and 10-years follow-up, and patients with apocrine carcinoma had good outcome until 5-years, with similar values to IBC-NST at 10-years. Patients with medullary carcinoma had the best DFS: based on the multivariate analysis medullary TNBC is an independent prognostic factor for DFS. Specific clinico-pathological and molecular features could explain the dissimilarities in the outcome of patients affected by TNBC with different histologic types.

Our results revealed that patients affected by invasive lobular carcinoma with triple negative phenotype had a poorer prognosis (79.7% at 5-years and 73.8% at 10-years) compared to all other histologic types. Triple negative invasive lobular carcinomas were mainly solid or mixed classic and solid variants, with only 3 cases showing morphologic features of pleomorphic variants. Our results showed that invasive lobular carcinoma represented a TNBC morphologic variant with higher lymph node ratio (\> 0.65), higher AR expression and lower TILs component, than those of other histologic special types. Moreover, 63% of triple negative invasive lobular carcinoma had a proliferation index (Ki-67) \> 15.0%.

Previous studies showed conflicting findings on the prognosis of lobular carcinoma patients compared to IBC-NST \[[@CR23], [@CR24]\], although prevalent data were obtained by analyzing ER-positive invasive lobular carcinoma and IBC-NST. Our results are supported by other authors' findings, especially when ER-negative invasive lobular carcinoma and IBC-NST were compared \[[@CR14], [@CR25]--[@CR28]\].

Recently, molecular analyses of invasive lobular carcinomas established that these tumors have a distinct genomic profile compared to IBC-NST, exhibiting a high frequency of *CDH1* mutations, loss of *PTEN*, activation of *AKT*, and mutations in *TBX3* and *FOXA1* \[[@CR29], [@CR30]\]. In addition, different studies found that patients with IBC-NST derive greater benefit from chemotherapy than patients diagnosed with invasive lobular carcinoma \[[@CR31]--[@CR35]\].

In the present study, metaplastic carcinoma resulted as a TNBC morphologic variant with poor prognosis, as previously described in the literature \[[@CR12]--[@CR14]\]. The 46 metaplastic carcinomas analyzed in this study exhibited high grade (91.1%), high Ki67 expression (84.4%), and presence of necrosis (83.7%), which might explain their poor prognosis. Interestingly, metaplastic breast cancers were found to express genes involved in epithelial mesenchymal transition and cell motility pathways, as observed in TNBC mesenchymal-like molecular subtype \[[@CR36], [@CR37]\]. The biological behavior of metaplastic carcinomas might be related to *β-Catenin* gene mutations and activation of WNT pathway \[[@CR36], [@CR38]\]. Furthermore, metaplastic tumors were included in mesenchymal-like molecular subtype based on their gene expression profile, characterized by PI3K/mTOR pathway aberrations, downregulation of genes involved in DNA repair and response to chemotherapy. These genetic deregulations could be responsible for the resistance to conventional chemotherapy showed by this histologic subtype \[[@CR39]\], in contrast with the general chemosensitivity of IBC-NST with Triple Negative phenotype.

In the current study, patients with medullary, apocrine and adenoid cystic carcinomas had better prognosis compared to IBC-NST. The classic medullary carcinomas analyzed in this study showed significantly high lymphocytic infiltrate (92.3%) and no lymphovascular invasion (92.6%), with an overall survival of 94.5% at 10-years follow-up, regardless of high grade and proliferation index. Recent studies demonstrated that immune signaling genes within the immunomodulatory molecular TNBC subtype substantially overlap with gene signature of medullary breast cancer \[[@CR36]--[@CR40]\]. The absence of lymphovascular invasion might explain the good prognosis of medullary carcinoma, which might be related to downregulation of genes associated with cell invasiveness \[[@CR40], [@CR41]\].

Furthermore, Denkert et al. described a quantitative assessment of TILs as a predictor of response to neoadjuvant chemotherapy \[[@CR42]\]. Retrospective analysis of clinical trials confirmed that TILs levels are predictive of pathologic complete response and increased disease-free and overall survival \[[@CR20], [@CR43]\].

In addition, recent evidence has shown the prognostic importance of high TILs in high grade BC such as medullary carcinoma, usually associated with good prognosis. Recently, the new WHO classification of Breast Tumors has included carcinoma with medullary features in the spectrum of TILs-rich IBC-NST, defined as IBC-NST with medullary pattern, and no longer as a distinct special subtype \[[@CR44]\]. Leon-Ferre et al. evaluated the prognostic role of TILs in TNBC patients who did not receive adjuvant chemotherapy, demonstrating that TILs is an independent prognostic factor in early-stage TNBC. They speculated that high TILs may represent the activation of an endogenous antitumor immune response that occurs even in the absence of immune enhancements triggered by chemotherapy. Specifically, univariate analysis showed that carcinomas with medullary features have better outcomes when compared to invasive carcinomas of NST, whereas this association was lost once TILs were included into a multivariate model \[[@CR45]\].

Recently, a higher immunohistochemical expression of PD-L1 known to be associated with immune evasion in a variety of malignancies, including TNBC, was identified in breast carcinomas with medullary features, in which might represent a marker of susceptibility to PD-1/PD-L1 inhibitor therapies \[[@CR46]\].

Our data showed that patients affected by apocrine carcinoma had better overall survival compared to IBC-NST at 5-years follow-up, while the OS was similar for the two histologic types at 10-years, showing concordance with results of Takeuchi et al. \[[@CR47]\]. Apocrine carcinomas were intermediate/high grade morphologic variants, with low lymph node ratio and high lymphocytic infiltrate and AR expression, and diagnosed at older age (41.9% at \> 70 years). AR signaling pathway activation is a prominent feature for apocrine lesions of the breast, representing a therapeutic opportunity by androgen therapies \[[@CR48]\]. So far, immunotherapies based on immune checkpoint inhibitors have not been specifically proposed for apocrine carcinomas, due to the low level or absent expression of PD-L1, in contrast to BC with triple negative phenotype, which is known to be variably PD-L1 positive (9--59%) \[[@CR46], [@CR49]\]. Our data highlighted a higher percentage of apocrine carcinomas with lymphocytic infiltrate (75.0%) than the percentage showed in IBC-NST (65.2%), suggesting that immunotherapies based on immune checkpoint inhibitors might be taken into consideration also for this TNBC special type.

Adenoid cystic carcinoma is a rare variant of breast cancer, accounting for less than 1% of all invasive breast cancers, which shows basal-like features and triple negative phenotype, but with a favorable clinical course. Although in our *TNBC Database* only six adenoid cystic carcinomas were available, namely 5 classic type and 1 solid-basaloid type, they were analyzed as a group according to its specificity and in accordance with other studies \[[@CR50]\]. Patients with adenoid cystic carcinoma had an OS of 100% at 10-years follow-up, with prevalently low/intermediate grade, low lymph node ratio, absence of necrosis, lymphocytic infiltrate, and AR expression. Uncommonly, our results showed that patients with adenoid cystic carcinoma had the highest rate of relapse (33.4%) among all histologic types. These results are conflicting and need a thorough analysis on a large casuistry. Furthermore, five case reports on patients with breast adenoid cystic carcinoma showing one or more distant metastasis have been published \[[@CR51]\]. Chen et al. using a large number of population-base data showed that breast adenoid cystic carcinoma has different pathological features and good clinical course compared to IBC-NST, but comparing BC *Triple Negative* phenotype no differences were shown between the two histologic types as far as recurrence and mortality are concerned \[[@CR52]\]. Patients with adenoid cystic carcinoma exhibited smaller size and limited distribution of tumor size than patients with IBC-NST (*p* = 0.050), according to the results of Mills et al. \[[@CR12]\]. Conversely, *Chen* et al. did not report any differences between tumor size in adenoid cystic carcinoma compared to IBC-NST \[[@CR47]\], while Kulkarn et al. found that patients with adenoid cystic carcinoma had larger median tumor size than patients with IBC-NST \[[@CR53]\].

Genetically, *MYB-NFIB* fusion gene is a prevalent feature of adenoid cystic carcinoma. Recently, a whole exome sequencing performed on 12 adenoid cystic carcinomas demonstrated that no somatic mutations in *TP53*, *PIK3CA*, *RB1*, *BRCA1* or *BRCA2* genes were identified in breast adenoid cystic carcinomas, unlike what occurs in common-type triple-negative and basal-like breast cancers. Interestingly, the mutational status of breast adenoid cystic carcinomas is more similar to those of salivary gland adenoid cystic carcinoma, than in other TNBCs types, emphasizing the importance of TNBCs histologic subtyping \[[@CR54]\].

Considering tumor size and lymph nodes status as significant clinico-pathological features in the choice of therapeutic regimens and in the prognosis of TNBC histologic types, the correlation between these parameters was analyzed. Tumor size and number of metastatic lymph nodes showed a positive correlation in apocrine and metaplastic carcinomas. Interestingly, by using a linear regression model it was observed that the increase of tumor size correlates with a great increase of average number of metastatic lymph nodes in apocrine carcinoma compared to IBC-NST. These data differ from Zhao et al. results, who demonstrated a positive correlation between tumor size and number of metastatic lymph nodes in different special types, such as lobular carcinoma and mixed ductal (NST)-lobular variants \[[@CR13]\].

Our study strengthens previous clinical and experimental data in favoring greater integration between histologic and molecular characterization of these variants, which should be considered together in the choice of therapeutic regimens.

Current clinical data indicate that patients with triple negative lobular or metaplastic carcinoma are less responsive to chemotherapy, contrary to patients affected by other TNBC histologic types, increasing the need to identify unambiguous molecular targets. Conversely, patients with TNBC histologic variants as medullary, apocrine and adenoid cystic carcinomas, both characterized by a more favorable prognosis, could be treated with less aggressive or even without chemotherapeutic regimens, according to the disease stage. Moreover, new therapeutic approaches, such as immunotherapy based on immune checkpoint inhibitors, or androgen-targeting therapies, should be evaluated in the treatment of TNBC patients according to histologic "*special types*".

The main limitation of this study is represented by inherent biases dependent on the retrospective nature of the design, notwithstanding three pathologists according to current WHO classification \[[@CR16]\] achieved definitive histologic subtyping of all the cases. Moreover, ER, PgR and HER2 immunohistochemical results for TNBC samples according to the ASCO/CAP recommendations were standardized \[[@CR17]\]. Unfortunately, for some patients important clinical and pathological data were missing because not originally included in the medical records, and those missing information might have influenced to some extent the evaluated associations.

Conclusions {#Sec10}
===========

The main conclusion of the present study is that clinico-pathological features and prognosis of TNBC differ according to histologic types. Adenoid cystic carcinoma, apocrine carcinoma and IBC-NST with medullary pattern, have in common a favourable prognosis, while invasive lobular carcinoma and metaplastic carcinoma are the most aggressive subtypes.

Our study confirms that an accurate and reliable histopathologic definition of TNBC subtypes has a significant clinical utility and is an effective tool during the therapeutic decision-making process, with the aim to develop innovative and personalized treatments.
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**Additional file 1:Figure S1.** Violin plot of tumor size distribution according to "Triple Negative" breast cancer histologic types. **Table S1.** Correlation between tumor size and number of metastatic lymph nodes in different histologic types of "Triple Negative" breast cancer. Sardinia, Italy 1994--2015. **Figure S2.** Correlation between tumor size and number of positive lymph nodes in "Triple Negative" breast cancer histologic types. A linear regression model constructs the regression lines. The slope of the regression line symbolizes the average increase in the number of metastatic lymph nodes for each millimeter increase in tumor size for each histologic TNBC types, indicative of the influence of tumor size on number of metastatic lymph nodes.
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